Tonix Pharmaceuticals Holding Corp. (TNXP)
Pre-Market:
| Previous Close | 0.1685 |
| Open | 0.1713 |
| Bid | 0.1779 x 400 |
| Ask | 0.1804 x 400 |
| Day's Range | 0.1651 - 0.1819 |
| 52 Week Range | 0.1200 - 3.3125 |
| Volume | |
| Avg. Volume | 2,271,416 |
| Market Cap | 17.15M |
| Beta (5Y Monthly) | 2.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Insider Monkey
20 Countries With The Highest Number of Drug Trafficking in the World
In this article, we will look at 20 countries with the highest number of drug trafficking in the world. If you want to skip our detailed discussion on drug abuse and trafficking in the United States, go to 5 Countries With The Highest Number of Drug Trafficking in the World. Drug abuse is one of […]
- Insider Monkey
Best Drug and Alcohol Rehab Centers in Each of 30 Biggest Cities in the US
In this article, we take a look at the Best Drug and Alcohol Rehab Centers in Each of the 30 Biggest Cities in the US. You can skip our detailed analysis and go directly to the Best Drug and Alcohol Rehab Centers in Each of 10 Biggest Cities in the US. Substance abuse is a […]
- Reuters
UPDATE 1-Tonix's long COVID drug fails to meet mid-stage trial goal
Tonix Pharmaceuticals Holding Corp said on Tuesday its experimental drug failed to meet the primary goal in a mid-stage study for management of widespread muscle pain and tenderness associated with long COVID-19. Shares of the company were down 12% in premarket trading. The 63-patient study was designed to monitor the intensity of pain in patients who had long COVID and administered either the drug, TNX-102 SL, or placebo, but the trial failed to show improvement at week 14 of treatment, the company said.
